Skip to main content

Table 2 All-grade AEs (occurring in ≥20 %) or grade 3–4 AEsa (occurring in >3 %) in phase 2a

From: Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Adverse event, n (%) Grades 1 and 2 Grade 3 Grade 4  
Group A (n = 22) Group B (n = 22) Group A (n = 22) Group B (n = 22) Group A (n = 22) Group B (n = 22) Total (N = 44)
Peripheral neuropathy 18 (81.8) 14 (63.6) 2 (9.1) 6 (27.3) 40 (90.9)
Fatigue 13 (59.1) 16 (72.7) 3 (13.6) 3 (13.6) 35 (79.5)
Nausea 9 (40.9) 9 (40.9) 1 (4.5) 1 (4.5) 20 (45.5)
Dry eye 6 (27.3) 11 (50.0) 1 (4.5) 18 (40.9)
Alopecia 6 (27.3) 11 (50.0) 17 (38.6)
Arthralgia 9 (40.9) 7 (31.8) 16 (36.4)
Epistaxis 5 (22.7) 11 (50.0) 16 (36.4)
Diarrhea 4 (18.2) 10 (45.5) 1 (4.5) 15 (34.1)
Thrombocytopenia 3 (13.6) 3 (13.6) 3 (14.6) 2 (9.1) 2 (9.1) 13 (29.5)
Decreased appetite 5 (22.7) 7 (31.8) 12 (27.3)
Neutropenia 1 (4.5) 5 (22.7) 3 (13.6) 2 (9.1) 1 (4.5) 12 (27.3)
Rash 2 (9.1) 9 (40.9) 1 (4.5) 12 (27.3)
Vision blurred 6 (27.3) 6 (27.3) 12 (27.3)
Myalgia 4 (18.2) 6 (27.3) 1 (4.5) 11 (25.0)
Dyspnea 3 (13.6) 7 (31.8) 10 (22.7)
Anemia 2 (9.1) 4 (18.2) 2 (9.1) 1 (4.5) 9 (20.5)
Constipation 4 (18.2) 4 (18.2) 1 (4.5) 9 (20.5)
Cough 4 (18.2) 5 (22.7) 9 (20.5)
Mucosal inflammation 1 (4.5) 4(18.2) 1 (4.5) 1 (4.5) 7 (15.9)
Muscular weakness 1 (4.5) 2 (9.1) 3 (6.8)
Decreased hemoglobin 1 (4.5) 1 (4.5) 2 (4.5)
  1. AE adverse event
  2. aNo patient experienced a grade 5 AE